Penn spinout company Verismo Therapeutics successfully raised $7 million in a pre-Series A round led by BRV Capital Management. The funds will be used to advance Verismo’s clinical trials for its SynKIR-110 therapy, with the goal of treating aggressive solid tumor malignancies such as mesothelioma and ovarian cancer. The proceeds from the round will also be used to continue preclinical development for Verismo’s SynKIR-310 therapy for diffuse large B-cell lymphoma and may help to advance additional future therapies.
In addition to the funding, Verismo also announced an expansion of its R&D partnership with Penn Medicine including a clinical cell manufacturing in partnership with the Clinical Cell and Vaccine Production Facility (CVPF) at the Perelman School of Medicine for clinical testing and potential use in a Phase I clinical trial to be conducted at Penn.